Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BCAX vs DAWN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DAWN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)

DAWN Overall Winner 6-Pillar Tally: BCAX 1 – 4 DAWN (1 Tie) Matrix Metrics: BCAX 2 – 6 DAWN

As of Nov 16, 2026, Day One Biopharmaceuticals, Inc. (DAWN) is the stronger overall head-to-head candidate over Bicara Therapeutics Inc. (BCAX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). BCAX carries a Unified Composite Score of 52.1/100 (HOLD) at $9.75 (N/M Forward P/E, 0.0% operating margin), whereas DAWN carries 58.3/100 (HOLD) at $21.53 (N/M Forward P/E, -51.1% operating margin).

  • Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile DAWN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 80.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BCAX vs DAWN
BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.75
-2.69% 1D
Market Cap $671.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.42β · 184% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.1%), weak momentum, RSI 33
RSI-14: 32.7 · SMA20: $11.85 · SMA50: $16.57
DAWN NASDAQ Head-to-Head Winner
Day One Biopharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$21.53
+0.19% 1D
Market Cap $2.2B
TTM Revenue $158M
Forward P/E N/M
Beta / 30D Vol 0.03β · 2% Vol
Unified Composite Score
58.3 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 66.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (28.9% over 20 days), RSI 80
RSI-14: 80.5 · SMA20: $21.45 · SMA50: $18.01

6-Pillar Scorecard Institutional Category Breakdown (BCAX 1 – 4 DAWN)

Columns: Metric · BCAX · DAWN
1. Valuation Multiples DAWN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 14.0x
2. Growth & Scale DAWN
Revenue Growth (YoY) +0.0% +83.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $158M
Market Cap $671.2M $2.2B
3. Profitability & Quality BCAX
Gross Margin N/A 89.1%
Operating Margin 0.0% -51.1%
Net Profit Margin 0.0% -67.8%
Return on Equity (ROE) -54.2% -22.7%
4. Balance Sheet & Cash Flow DAWN
Cash Generation (TTM) -$163M -$124M EBITDA
Cash Flow Margin N/A -78.6% EBITDA Mgn
Net Cash / Leverage $81M Net Cash $4.28 Book/Sh · -22.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DAWN
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 102.7% (23rd %ile) 0.6% (<1st %ile)
Put/Call OI Skew N/A 0.45x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BCAX (2) vs DAWN (6)
Institutional Metric BCAX DAWN Criterion Row Edge
Market Capitalization
Scale
$671.2M $2.2B Larger Scale DAWN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +83.9% Higher Growth DAWN
Operating Margin (TTM)
Profitability
0.0% -51.1% Higher Margin BCAX
Net Profit Margin
Profitability
0.0% -67.8% Higher Margin BCAX
Return on Equity (ROE)
Capital Efficiency
-54.2% -22.7% Higher ROE DAWN
52-Week Range Position
Momentum
8% ($8–$31) 100% ($6–$22) Stronger Trend DAWN
Beta / 30D Volatility
Risk Regime
1.42β · 184% Vol 0.03β · 2% Vol Lower Realized Risk DAWN
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 58.3 / 100 (HOLD) Higher Composite DAWN
Trailing 12M Revenue (USD)
Operating Scale
N/A $158M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 89.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 14.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$163M ($81M Net Cash) -$124M EBITDA ($4.28 Book/Sh · -22.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BCAX +27.69 pp
BCAX: +28.49% · DAWN: +0.8%
3M Horizon DAWN +39.13 pp
BCAX: +39.25% · DAWN: +78.38%
6M Horizon DAWN +77.57 pp
BCAX: +65.71% · DAWN: +143.28%
1Y Horizon DAWN +77.57 pp
BCAX: +65.71% · DAWN: +143.28%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs DAWN. Trailing 12-month operating profitability (BCAX 0.0% vs DAWN -51.1%) and valuation multiples (BCAX N/M vs DAWN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BCAX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-54.2% · N/M
DAWN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$158M
Gross Margin89.1%
Op. Margin-51.1%
ROE / Fwd P/E-22.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BCAX BREAKDOWN
93d in phase · OBV ACCUMULATION
Current IV 102.7%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact BCAX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DAWN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.6%
IV Percentile <1st %ile
Put/Call OI Skew 0.45x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact DAWN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BCAX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $671.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DAWN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and -51.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BCAX vs DAWN Key Questions & Quantitative Answers

As of Nov 16, 2026, Day One Biopharmaceuticals, Inc. (DAWN) is the stronger overall head-to-head candidate over Bicara Therapeutics Inc. (BCAX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). BCAX carries a Unified Composite Score of 52.1/100 (HOLD) at $9.75 (N/M Forward P/E, 0.0% operating margin), whereas DAWN carries 58.3/100 (HOLD) at $21.53 (N/M Forward P/E, -51.1% operating margin). Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile DAWN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 80.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DAWN leads the Growth & Scale pillar: BCAX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DAWN at +83.9% YoY revenue growth and +0.0% YoY earnings growth on $158M TTM revenue (89.1% gross margin, -51.1% operating margin). On trailing 12-month operating scale, BCAX generates N/A in USD-normalized revenue versus $158M for DAWN. In operating R&D and SG&A reinvestment, BCAX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DAWN.

DAWN screens cheaper on headline valuation multiples. BCAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DAWN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.0x EV/Revenue (-78.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BCAX (-54.2% ROE) versus DAWN (-22.7% ROE) capital efficiency.

In options market volatility and institutional positioning, BCAX carries 102.7% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.42β · 184% Vol realized risk). By comparison, DAWN carries 0.6% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.45x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.03β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.